Purpose Tools to estimate survival, such as ePrognosis (http://eprognosis.ucsf.edu/carey2.php), were developed for general, not cancer, populations. In older patients with breast cancer, accurate overall survival estimates would facilitate discussions about adjuvant therapies. Methods Secondary analyses were performed of data from two parallel breast cancer studies (CALGB/Alliance 49907/ NCT000224102 and CALGB/Alliance 369901/NCT000 68328). We included patients (n = 971) who were age 70 years and older with complete baseline quality of life data (194 from 49907; 777 from 369901). Estimated versus observed all-cause two-year mortality rates were compared. ePrognosis score was calculated based on age, sex, and daily function (derived from EORTC QLQ-C30). ePrognosis scores range from 0 to 10, with higher scores indicating worse prognosis based on mortality of community-dwelling elders and were categorized into three groups (0-2, 3-6, 7-10). Observed mortality rates were estimated using Kaplan-Meier methods. Results Patient mean age was 75.8 years (range 70-91) and 73% had stage I-IIA disease. Most patients were classified by ePrognosis as good prognosis (n = 562, 58% 0-2) and few (n = 18, 2% 7-10) poor prognosis. Two-year observed mortality rates were significantly lower than ePrognosis estimates for patients scoring 0-2 (2% vs 5%, p = 0.001) and 3-6 (8% vs 12%, p = 0.01). The same trend was seen with scores of 7-10 (23% vs 36%, p = 0.25).
Introduction
Cancer systemic adjuvant therapy prevents future distant recurrences and improves long-term survival [1] . In older patients, the balance of benefits and risks of cancer treatment is complicated by competing causes of mortality, presence of frailty, and advanced age. These factors are associated with increase treatment toxicity and limited overall and cancer-specific survival and, therefore, hinder discussions about preventive therapies and participation in clinical trials [2, 3] . Data on life expectancy could support treatment decision-making. Several extant tools are available to estimate life expectancy in older individuals, and they are compiled for clinical use in ePrognosis (http://eprognosis.ucsf.edu/) [4] . The ePrognosis tools were designed for older adults without severe illnesses, such as cancer, and are validated in community-dwelling, nursing-home, or hospitalized older individuals. None of these indices is validated in patients with non-metastatic cancer, who might be considering potentially curative adjuvant therapies.
We conducted a secondary analysis of data from two cancer cooperative group studies to compare short-term (twoyear) ePrognosis estimated versus observed all-cause mortality rates among older women with non-metastatic breast cancer. Studies included were (1) a phase III, randomized study of adjuvant chemotherapy for breast cancer in women age 65 years and older (CALGB 49907/NCT000224102) [5] and (2) a parallel observational study with the same eligibility criteria (CALGB 369901/NCT00068328) [6] . CALGB is now a part of the Alliance for Clinical Trials in Oncology. By design, the two studies included a common core of sociodemographic and quality of life data [7] .
Methods
This study was deemed exempt by the Duke University Hospital System Institutional Review Board.
Patients with early-stage breast cancer participating in CALGB/Alliance 49907 and 369901, who were age 70 years and older and had completed baseline quality of life questionnaires, were included in the analysis (Fig. 1) . Age 70 years was chosen to parallel ePrognosis. We selected two-year all-cause mortality because short-term limits in life expectancy would have a large influence on systemic therapy decisions, particularly among women with estrogen-receptor negative breast cancer. Cause of death was grouped as breast cancer-related and other, which included unknown, cause.
Estimations of prognosis
The two-year ePrognosis tool [8] was developed from the Asset and Health Dynamics Among the Oldest Old (AHEAD) study of 4516 community-dwelling adults, age 70 years and older, and provides mortality estimates based on answers to six function questions. We matched data items collected from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at baseline to the ePrognosis tool.
The ePrognosis tool assigns a score to each item, for a summary score ranging from 1 to 10, with zero indicating the best prognosis. We applied the scoring system to the study data as follows: 
Statistical analysis
Observed all-cause mortality rates (and 95% confidence intervals) were calculated for both samples combined and each protocol separately from study entry to death using Kaplan-Meier methods [9, 10] . All-cause mortality rates were also calculated for each stratum of the ePrognosis score categories (0-2 points, 3-6 points, and 7-10 points).
Observations were censored at the date last known alive.
The two-year survival Index scores from ePrognosis were used to generate an estimated survival rate for each score category. A two-sided z test was used to compare the observed versus estimated mortality rates. Data collection and statistical analyses were conducted by the Alliance Statistical and Data Center. All analyses were conducted using SAS Version 9.4 (SAS Institute, Cary, NC, USA) on a dataset locked on May 15, 2015.
Results
Participant mean age was 76 years with range of 70-91 years. Patient characteristics, overall and by study, are presented in Table 1 . Of those that died within 2 years, 55% died from causes related to breast cancer. Most women were in the good prognosis category (n = 562, 58%) and 18 (2%) in the poor prognosis category. Predicted and observed mortality estimates by ePrognosis are shown in Table 2 and Appendix Fig. 1 . Two-year observed mortality was significantly lower than estimated from ePrognosis for patients scoring 0-2 (2% vs 5%, p = 0.001) and 3-6 (8% vs 12%, p = 0.01) points.
Although not significant, the same trend was seen for the small number with scores of 7-10 (23% vs 36%, p = 0.25).
The results are similar within each study (Appendix Table 1 and Figs. 2 and 3 ).
Discussion
Older women with non-metastatic breast cancer participating in cooperative group studies have very low two-year all-cause mortality rates. The ePrognosis tool systematically, but only slightly, overestimated mortality. This may have implications for practice, since the tool may be used by clinicians when discussing systemic treatment options that have short-term toxicity but long-term benefits in preventing recurrence [1] .
These results are consistent with studies of linked SEER-Medicare datasets showing that women age 65 years and older with early-stage breast cancer have higher nonbreast cancer survival than matched women without breast cancer [11, 12] . Higher socio-economic status, healthier behaviors, better healthcare access, and more routine doctor visits to treat coexisting illness are thought to explain the better non-breast cancer survival seen in older breast cancer patients [11, 13, 14] . Use of older datasets to derive ePrognosis estimates and lower mortality over time due to improvements in management of acute toxicities and comorbidities may also explain why ePrognosis provided an overestimate [15] . Interestingly, other online prognostic tools, such as Adjuvant! Online and PREDICT, also slightly overestimate 10-year survival [16, 17] . This study is limited by the secondary nature of the analysis, some non-correspondence between items on the tool and those available from EORTC, and use of cooperative group data. These results will need to be confirmed in broader, older breast cancer populations, and community settings. However, the prospective design of the original studies, high quality of data collection, and inclusion of many community hospitals, and observational data enhances the generalizability of the finding.
Despite these caveats, the results were robust across datasets and prognostic groups and suggest that tools developed in general populations provide a slight overestimate of mortality in older breast cancer patients, which may not be clinically significant. Even so, development and testing of more accurate tools to estimate mortality in older breast cancer patients could enhance shared decisionmaking about the risks and benefits of adjuvant therapies. 
